Cannabis ETFs
0 stocks · Updated Mar 25, 2026
Cannabis ETFs provide diversified exposure to the legal marijuana industry without the risk concentration of individual cannabis stocks. After the spectacular 2018-2019 cannabis bubble and subsequent multi-year bear market, cannabis ETFs trade at a fraction of their peak values. The investment thesis today centers on US federal legalization or rescheduling as a potential catalyst for MSO uplistings, banking access, and institutional investment that could trigger a significant re-rating.
Get Your Daily Market Recap
TickFlow Daily delivers the top gainers, losers, and signals to your inbox every day at market close. Free.
Frequently Asked Questions
Why have cannabis ETFs performed so poorly?
Cannabis ETFs are down 80-95% from 2019 peaks due to: failed federal legalization timelines, state-level oversupply depressing prices and margins, 280E tax burden, capital market access limitations for US operators, and illicit market competition.
What would federal legalization do for cannabis ETFs?
Federal legalization or Schedule III rescheduling would eliminate the 280E tax burden (transformative for profitability), allow banking access, enable interstate commerce, and potentially trigger large CPG and beverage company acquisitions at premiums.
What are the largest cannabis ETFs?
MSOS (AdvisorShares Pure US Cannabis) focuses on US multi-state operators. MJ (ETFMG Alternative Harvest) is a global cannabis ETF with Canadian LP exposure. THCX (Cannabis ETF) and YOLO (Cannabis ETF) are also notable options.
Should I own a cannabis ETF or individual cannabis stocks?
Cannabis ETFs provide diversification across the high-risk cannabis sector, reducing single-operator binary risk. Individual stock selection can outperform if you correctly identify the operators with best cost structures, state market positions, and balance sheet strength.